Short Interest in InterCure Ltd. (NASDAQ:INCR) Expands By 72.6%

InterCure Ltd. (NASDAQ:INCRGet Free Report) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 47,234 shares, an increase of 72.6% from the May 31st total of 27,374 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily volume of 74,696 shares, the days-to-cover ratio is currently 0.6 days.

InterCure Stock Down 3.5%

NASDAQ:INCR opened at $1.09 on Friday. InterCure has a 1 year low of $0.68 and a 1 year high of $1.77. The stock has a 50-day moving average price of $0.94 and a two-hundred day moving average price of $0.92. The stock has a market cap of $59.60 million, a price-to-earnings ratio of 36.33 and a beta of 1.39. The company has a current ratio of 1.48, a quick ratio of 0.97 and a debt-to-equity ratio of 0.20.

InterCure (NASDAQ:INCRGet Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $23.15 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of InterCure in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, InterCure presently has an average rating of “Sell”.

Get Our Latest Report on InterCure

About InterCure

(Get Free Report)

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.

Featured Articles

Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.